EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Open label clinical trial of orally administered molnupiravir as a first-line treatment for naturally occurring effusive feline infectious peritonitis

Krystle L Reagan iD, Terza Brostoff, Jully Pires, Amy Rose, Diego Castillo, Brian G Murphy

Journal of Veterinary Internal Medicine · 2024

DOI: 10.1111/jvim.17187 ↗

At a glance

Journal article in Journal of Veterinary Internal Medicine, 2024. Written by Krystle L Reagan and 5 co-authors. Institution: Department of Veterinary Medicine and Epidemiology, University of California, Davis, School of Veterinary Medicine, Davis, California, USA. Major MEDLINE topics: Feline Infectious Peritonitis, Antiviral Agents, Hydroxylamines. Cited 10 times so far (Crossref); 24 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: SOCK FIP and Center for Companion Animal Health, EveryCat Health Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Before the discovery of effective antiviral drugs, feline infectious peritonitis (FIP) was a uniformly fatal disease of cats. Multiple antiviral treatments have been recognized, but optimization of treatment protocols is needed.

Objective

To evaluate the efficacy of PO molnupiravir (MPV; EIDD-2801) to treat effusive FIP. Animals Ten cats with naturally occurring effusive FIP and 10 historical control cats with effusive FIP treated with PO GS-441524.

Methods

A single-center, prospective, open-label longitudinal, non-inferiority trial with historical controls. Ten cats with FIP were enrolled and treated with PO MPV (10-15 mg/kg PO q12h) for 84 days. Cats were evaluated at 0, 6, and 16 weeks, and the proportion of cats in clinical remission at 16 weeks was determined. Survival and clinicopathologic features were compared with historical control cats with effusive FIP treated with PO GS-441524.

Results

Eight of the 10 cats treated with MPV survived and were in remission at 16 weeks. The 2 non-survivors died in the first 24 hours of treatment. No adverse events that necessitated discontinuation of treatment were observed. Survival of cats treated with PO MPV was non-inferior to historic control cats treated with PO GS-441524 (5/9 [55%] survived), with a difference in survival of 25% (90% confidence interval, −9.3% to 59.3%). Clinicopathologic features associated with FIP normalized during the study period, and no differences in clinicopathologic data at each study time point were observed when comparing cats treated with MPV and GS-441524. Conclusions and Clinical Importance Molnupiravir is an effective antiviral treatment for effusive FIP.

Subjects

MeSH terms (MEDLINE)

Feline Infectious PeritonitisAntiviral AgentsHydroxylaminesAnimalsCatsMaleFemaleProspective StudiesAdministration, OralUridine MonophosphateCytidineLongitudinal StudiesUridineAdenosine

Author keywords

FIPantiviralfeline coronavirusinfection

Substances

Antiviral AgentsmolnupiravirHydroxylaminesUridine MonophosphateCytidineGS-441524UridineAdenosine

Authors and institutions

  • Department of Veterinary Medicine and Epidemiology, University of California, Davis, School of Veterinary Medicine, Davis, California, USA.
  • Department of Pathology, Microbiology, and Immunology, University of California, Davis, School of Veterinary Medicine, Davis, California, USA.
  • Veterinary Center for Clinical Trials, University of California, Davis, School of Veterinary Medicine, Davis, California, USA.

ORCID profiles: Krystle L Reagan

Funding

  • SOCK FIP and Center for Companion Animal Health
  • EveryCat Health Foundation

Cite

APA

Reagan, K. L., Brostoff, T., Pires, J., Rose, A., Castillo, D., & Murphy, B. G. (2024). Open label clinical trial of orally administered molnupiravir as a first-line treatment for naturally occurring effusive feline infectious peritonitis. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17187

Vancouver

Reagan KL, Brostoff T, Pires J, Rose A, Castillo D, Murphy BG. Open label clinical trial of orally administered molnupiravir as a first-line treatment for naturally occurring effusive feline infectious peritonitis. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17187

BibTeX
@article{Reagan2024,
  author = {Reagan, Krystle L and Brostoff, Terza and Pires, Jully and Rose, Amy and Castillo, Diego and Murphy, Brian G},
  title = {Open label clinical trial of orally administered molnupiravir as a first-line treatment for naturally occurring effusive feline infectious peritonitis},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  doi = {10.1111/jvim.17187}
}
Start for free →